These findings validate this methodology as a novel in vitro technique for the quantification of TDP-43 or FUS mislocalisation that can be used for initial prioritisation of predicted FTD/ALS-causative mutations. The gene discussed is FUS; the disease is amyotrophic lateral sclerosis.